AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company that develops and commercializes innovative therapies for the treatment of acute pain. The company is headquartered in Redwood City, California, and was founded in 2005.
AcelRx Pharmaceuticals is focused on developing and commercializing innovative therapies that address unmet needs in the management of acute pain. The company's lead product candidate, DSUVIA (sufentanil sublingual tablet), is a potent opioid analgesic that is designed to provide rapid and effective pain relief in a variety of clinical settings.
DSUVIA has been approved by the U.S. Food and Drug Administration (FDA) for use in adults in medically supervised settings, such as hospitals and surgical centers, and has demonstrated superior pain relief compared to placebo in clinical studies. The drug is administered sublingually, or under the tongue, providing a non-invasive and convenient route of administration.
In addition to DSUVIA, AcelRx Pharmaceuticals is also developing Zalviso (sufentanil sublingual microtablet system), a patient-controlled analgesia system that is designed to provide on-demand pain relief in the hospital setting. The drug has been approved for use in the European Union and is currently undergoing clinical trials in the United States.
The global acute pain market is expected to reach $12.7 billion by 2026, according to a report by Grand View Research. With its focus on developing innovative therapies for acute pain management, AcelRx Pharmaceuticals is well-positioned to capitalize on the expanding market.
AcelRx Pharmaceuticals is led by a team of experienced professionals with a deep understanding of the pharmaceutical industry. The company's management team has a proven track record of success in drug development and commercialization, and is committed to delivering value to its investors through a disciplined investment approach.
AcelRx Pharmaceuticals is a specialty pharmaceutical company that is focused on developing innovative therapies for the treatment of acute pain. With a strong product pipeline and a commitment to delivering value to its investors, the company is well-positioned to drive growth in the years ahead.